Trial Profile
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 05 Aug 2014 Pharmacokinetic results presented at the Digestive Disease Week 2014.
- 05 Aug 2014 Posthoc results presented at the Digestive Disease Week 2014.
- 21 May 2013 Results presented at the Digestive Disease Week 2013.